Developer docs
API playgroundTry for free, no card

Search company profiles

Codex Genetics

Full company profile

uuid002uuuj

Namestring
Codex Genetics
Legal namestring
Codex Genetics Limited
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Codex Genetics is a precision genomics company founded in 2013 and headquartered in Hong Kong, operating an accredited molecular diagnostics platform that delivers Next-Generation Sequencing-based clinical genetic testing for hereditary cancers, neurodegenerative diseases, cardiovascular disorders, pharmacogenomics, neurodevelopmental conditions, rare and undiagnosed diseases, and cancer screening/monitoring (including liquid biopsy). Its technology stack combines Illumina NextSeq 2000 sequencing with the proprietary CoGenesis® Bioinformatics Platform for DNA alignment and variant annotation, and includes plasma-based single-molecule immuno-detection of Alzheimer's biomarkers (p-tau217, Aβ42/40 ratio, NfL) alongside APOE genotyping. The company maintains dual ISO 15189 (HOKLAS) and ISO 27001 certifications, achieves 99.9% sequencing accuracy validated by GenQA/UK NEQAS, and holds CAP accreditation for APOE genotyping.

The portfolio comprises a CoGenesis® brand family of 41 tests including CoGenesis® Cancer, CoGenesis® Neuro, CoGenesis® BRCA-Pro (29-gene hereditary breast/ovarian panel), CoGenesis® CVD, and an Alzheimer's Disease Plasma Biomarker Panel, supplemented by whole-genome sequencing and the exclusive Hong Kong distribution of C2N Diagnostics' PrecivityAD2™ Alzheimer's blood test. Codex serves three customer segments — patients, healthcare providers, and biopharma/research institutions — through distinct portals. Patients access tests directly via the shop.codexgenetics.com e-commerce storefront; healthcare providers requisition tests through a dedicated For Providers portal with downloadable forms and direct WhatsApp/phone clinical support; biopharma clients engage for research services and clinical trial management.

Revenue is generated predominantly on a unit-pricing, one-time test basis with per-test pricing ranging from $100 to over $2,000 depending on complexity. The company partners with ZA Insure to broaden insured-patient access and serves over 200 healthcare partners across Hong Kong. The business has been primarily bootstrapped since the $41,250 Cyberport Hong Kong seed round in 2014, with no subsequent disclosed institutional funding rounds, parent company, or acquisitions.

Short descriptiontext

Hong Kong-based molecular diagnostics company providing NGS-based genetic testing for hereditary cancer, neurodegenerative, cardiovascular, and pharmacogenomic conditions. It serves patients, clinicians, and biopharma via clinician referrals and direct e-commerce, powered by its proprietary CoGenesis® bioinformatics platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWan Chai, Hong Kong SAR China
HQ citystring
Wan Chai
HQ countrystring
Hong Kong SAR China
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hereditary cancer testing, molecular diagnostics services, pharmacogenomics testing, next-generation sequencing, neurodegenerative disease panels
Industry3 codes
PRIMARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
NAICS code2 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Molecular Diagnostics & Genetic Testing Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Genetic Testing Services
TypeSubscription Recurring
Description

Codex Genetics generates revenue through clinical genomic tests ordered by healthcare providers and directly by patients via their E-Shop (shop.codexgenetics.com). Tests include hereditary cancer panels, neurodegenerative disease panels, pharmacogenomics, cardiovascular disorder panels, and cancer screening/monitoring. Costs range from $100 to over $2,000 depending on the test complexity.

codexgenetics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others
Pricing details4 tiers
1Hereditary Cancer Panels (e.g., CoGenesis® BRCA-Pro — 29-gene panel)
ModelUnit PricingBilling cadenceOne time/ perpetual license
Notes

Hereditary cancer panel tests (e.g., CoGenesis® BRCA-Pro, Gastric, Prostate, Colo) range from $100 to over $2,000 depending on the panel complexity. Turnaround 4–6 working weeks.

codexgenetics.com
2Neurodegenerative Disease Panels (e.g., CoGenesis® Neuro, Alzheimer's Plasma Biomarker)
ModelUnit PricingBilling cadenceOne time/ perpetual license
Notes

Comprehensive neurological disorder panels and Alzheimer's disease plasma biomarker panels (APOE genotyping and p-tau217, Aβ42/40, NfL) range from $100 to over $2,000. Turnaround 14–21 working days (plasma biomarker panel).

codexgenetics.com
3Pharmacogenomics (PGx) Tests
ModelUnit PricingBilling cadenceOne time/ perpetual license
Notes

Gene-drug interaction summary tests; range from $100 to over $2,000.

codexgenetics.com
4Cardiovascular Disorder Panels (e.g., CoGenesis® CVD)
ModelUnit PricingBilling cadenceOne time/ perpetual license
Notes

Comprehensive hereditary cardiovascular disease panel. Turnaround ~3–4 working weeks. Range from $100 to over $2,000.

codexgenetics.com
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 6 records shown
1CoGenesis Cancer
Description

Hereditary cancer test panels including BRCA-Pro, Gastric, Prostate, and Colo tests using Next-Generation Sequencing

codexgenetics.com
+5 more records
Core offering1 text field

Codex Genetics operates a clinical molecular diagnostics laboratory providing genetic testing services across hereditary cancer, neurodegenerative disease, pharmacogenomics, cardiovascular disorders, neurodevelopmental conditions, liquid biopsy, and whole-genome sequencing. Tests are delivered under the CoGenesis® brand via Next-Generation Sequencing (Illumina NextSeq 2000) combined with the proprietary CoGenesis® Bioinformatics Platform, and are ordered either by healthcare providers through a dedicated clinical portal or directly by patients via the Codex E-Shop.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 90% accuracy compared to cerebrospinal fluid analysis or amyloid PET analysis for the PrecivityAD2 blood test (JAMA-published clinical care study)
+3 more records
Product overview1 text field

Codex Genetics offers a molecular diagnostics platform providing genetic testing services across multiple clinical areas including hereditary cancer, neurodegenerative diseases, cardiovascular disorders, neurodevelopmental disorders, drug response (pharmacogenomics), cancer screening, treatment guidance, and monitoring. The portfolio includes branded test panels under the CoGenesis® brand (CoGenesis® Cancer, CoGenesis® Neuro, CoGenesis® BRCA-Pro, CoGenesis® CVD) plus specialized biomarker panels and whole-genome sequencing. The company operates on an NGS-based technology platform using the Illumina NextSeq 2000 System, with bioinformatics analysis powered by the CoGenesis® Bioinformatics Platform. All tests leverage Next-Generation Sequencing for comprehensive analysis and are supported by HKAS HOKLAS accreditation and ISO certifications. The company also provides distribution services for third-party diagnostic products such as the PrecivityAD2 blood test in partnership with C2N Diagnostics.

Product and service9 records
1CoGenesis® Cancer Panel
CategoryHereditary Cancer Genetic Testing
Description

Flagship hereditary cancer test panel using Next-Generation Sequencing to detect risks for hereditary cancers, including BRCA-Pro (29-gene hereditary breast and ovarian cancer), Gastric, Prostate, and Colo panels. Delivered with NCCN-aligned actionable recommendations. Turnaround 4-6 working weeks.

2CoGenesis® Neuro Panel
CategoryNeurodegenerative Disease Genetic Testing
Description

Comprehensive genomic panel for unexplained neurological disorders, including APOE genotyping for Alzheimer's disease risk assessment. Aimed at neurologists and patients with neurodegenerative concerns. Turnaround 2-4 weeks for AD/APOE components.

3CoGenesis® BRCA-Pro
CategoryHereditary Cancer Genetic Testing
Description

29-gene hereditary breast and ovarian cancer test providing risk assessment with well-stratified risk and actionable NCCN-aligned recommendations. Turnaround under 21 days.

4CoGenesis® CVD
CategoryCardiovascular Genetic Testing
Description

Comprehensive hereditary cardiovascular disease panel for identifying genetic predispositions to heart conditions. Turnaround approximately 3-4 working weeks.

5Alzheimer's Disease Plasma Biomarker Panel
CategoryNeurodegenerative Disease Biomarker Testing
Description

Validated plasma biomarkers for Alzheimer's disease combining APOE genotyping via sequencing with single-molecule immuno-detection of p-tau217, Aβ42/40 ratio, and NfL. Turnaround 14-21 working days. Aligned with NIA-AA 2024 criteria.

6Whole-Genome Sequencing
CategoryWhole Genome Sequencing
Description

Comprehensive sequencing service covering the entire genome for rare disease diagnoses, diagnostic odyssey resolution, and detailed genetic analysis. Suitable for pediatric developmental delay investigation.

7Liquid Biopsy
CategoryOncology Liquid Biopsy
Description

Non-invasive blood-based testing for cancer detection, screening, treatment guidance, and monitoring, used in oncology workflows.

8Pharmacogenomics (PGx)
CategoryPharmacogenomic Testing
Description

Drug response genetic testing that personalizes medication and treatment plans based on genetic profiles, including gene-drug interaction summaries to prevent adverse drug reactions and inform prescribing.

9PrecivityAD2 Blood Test
CategoryNeurodegenerative Disease Blood Testing
Description

Blood-based test for early detection and diagnosis of Alzheimer's disease, distributed by Codex Genetics in Hong Kong under exclusive partnership with C2N Diagnostics; offered to hospitals, specialty clinics, and research centers.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-10
Description

Codex Genetics partnered with C2N Diagnostics to launch the PrecivityAD2™ blood test for Alzheimer's disease diagnosis in Hong Kong. C2N provides its proprietary assay technology and analytical platform; Codex Genetics handles local regulatory compliance, distribution, and patient access to hospitals, specialty clinics, and research centers. The collaboration aims to support early intervention strategies and clinical trial enrollment.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-08
Description

C2N Diagnostics expansion of the PrecivityAD2 blood test to over seven additional countries through six new international partners including Codex Genetics. Codex serves as the exclusive distributor for Hong Kong. The blood test has demonstrated over 90% accuracy compared to cerebrospinal fluid analysis or amyloid PET analysis (JAMA-published study).

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Codex Genetics partners with ZA Insure to enhance test accessibility through insurance coverage, allowing patients to potentially offset testing costs through health insurance.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Hong Kong-headquartered genetic and diagnostic testing company offering hereditary cancer screening, pharmacogenomics, and consumer health tests across Asia. Closest geographic and product peer to Codex Genetics, competing for similar Hong Kong clinical and consumer customers.

TypeDirect peer
Description

Asia-based (Korea) genomic services and NGS sequencing provider offering clinical and research sequencing, hereditary cancer panels, and bioinformatics. Comparable to Codex in NGS-based clinical panel offerings and target customers across research and clinical markets.

TypeBroad incumbent
Description

US-based molecular diagnostics company (Roche subsidiary) specializing in comprehensive genomic profiling for cancer. Comparable NGS-based cancer genomics testing capability to Codex's CoGenesis® Cancer and liquid biopsy panels.

TypeBroad incumbent
Description

US-based genetic testing company with hereditary cancer (Signatera), reproductive health, and organ transplant testing. Comparable NGS-based clinical genetic testing portfolio and oncology-monitoring positioning similar to Codex's liquid biopsy offering.

TypeRegional player
Description

China-based clinical diagnostic laboratory network offering genetic and molecular testing, including hereditary cancer panels, across mainland China. Comparable clinical lab business model with NGS-based testing menu, primarily serving mainland China and not directly competing in Hong Kong.

TypeDirect peer
Description

US-based genetic testing company specializing in hereditary cancer panels and population health genomics. Directly comparable hereditary cancer testing offering and clinical accuracy emphasis to Codex's CoGenesis® Cancer and BRCA-Pro panels.

TypeBroad incumbent
Description

US-based molecular diagnostics leader with strong hereditary cancer franchise (BRACAnalysis, myRisk). Comparable hereditary cancer panel product and NCCN-aligned reporting standard referenced in Codex's BRCA-Pro offering.

TypeDirect peer
Description

China-based genomics services company providing NGS, whole-genome sequencing, and clinical genetic testing across Asia and globally. Directly comparable NGS-based clinical testing menu (hereditary cancer, rare disease, oncology) to Codex's CoGenesis® panels.

TypeBroad incumbent
Description

US-based direct-to-consumer genetic testing company offering health risk and carrier screening tests. Comparable consumer-facing hereditary health risk testing business model, though operating at much larger scale and in different geographies.

TypeBroad incumbent
Description

Largest Chinese genomics conglomerate offering clinical NGS testing, NIFTY prenatal screening, and cancer diagnostics across Asia. Comparable in menu breadth and Asian market focus, with substantially greater scale and vertically integrated sequencing capacity.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Codex Genetics

Molecular Diagnostics & Genetic Testing Servicescodexgenetics.com

Hong Kong-based molecular diagnostics company providing NGS-based genetic testing for hereditary cancer, neurodegenerative, cardiovascular, and pharmacogenomic conditions. It serves patients, clinicians, and biopharma via clinician referrals and direct e-commerce, powered by its proprietary CoGenesis® bioinformatics platform.

What Codex Genetics does

Codex Genetics is a precision genomics company founded in 2013 and headquartered in Hong Kong, operating an accredited molecular diagnostics platform that delivers Next-Generation Sequencing-based clinical genetic testing for hereditary cancers, neurodegenerative diseases, cardiovascular disorders, pharmacogenomics, neurodevelopmental conditions, rare and undiagnosed diseases, and cancer screening/monitoring (including liquid biopsy). Its technology stack combines Illumina NextSeq 2000 sequencing with the proprietary CoGenesis® Bioinformatics Platform for DNA alignment and variant annotation, and includes plasma-based single-molecule immuno-detection of Alzheimer's biomarkers (p-tau217, Aβ42/40 ratio, NfL) alongside APOE genotyping. The company maintains dual ISO 15189 (HOKLAS) and ISO 27001 certifications, achieves 99.9% sequencing accuracy validated by GenQA/UK NEQAS, and holds CAP accreditation for APOE genotyping.

The portfolio comprises a CoGenesis® brand family of 41 tests including CoGenesis® Cancer, CoGenesis® Neuro, CoGenesis® BRCA-Pro (29-gene hereditary breast/ovarian panel), CoGenesis® CVD, and an Alzheimer's Disease Plasma Biomarker Panel, supplemented by whole-genome sequencing and the exclusive Hong Kong distribution of C2N Diagnostics' PrecivityAD2™ Alzheimer's blood test. Codex serves three customer segments — patients, healthcare providers, and biopharma/research institutions — through distinct portals. Patients access tests directly via the shop.codexgenetics.com e-commerce storefront; healthcare providers requisition tests through a dedicated For Providers portal with downloadable forms and direct WhatsApp/phone clinical support; biopharma clients engage for research services and clinical trial management.

Revenue is generated predominantly on a unit-pricing, one-time test basis with per-test pricing ranging from $100 to over $2,000 depending on complexity. The company partners with ZA Insure to broaden insured-patient access and serves over 200 healthcare partners across Hong Kong. The business has been primarily bootstrapped since the $41,250 Cyberport Hong Kong seed round in 2014, with no subsequent disclosed institutional funding rounds, parent company, or acquisitions.

Codex Genetics firmographics

Firmographics
Name
Codex Genetics
Legal name
Codex Genetics Limited
Website
https://codexgenetics.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Hong Kong-based molecular diagnostics company providing NGS-based genetic testing for hereditary cancer, neurodegenerative, cardiovascular, and pharmacogenomic conditions. It serves patients, clinicians, and biopharma via clinician referrals and direct e-commerce, powered by its proprietary CoGenesis® bioinformatics platform.
Ownership category
akta.pro rank

Codex Genetics industry classification

Industry
Product category
Molecular Diagnostics & Genetic Testing Services
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)

Keywords

  • Hereditary cancer testing
  • Molecular diagnostics services
  • Pharmacogenomics testing
  • Next-generation sequencing
  • Neurodegenerative disease panels

Where Codex Genetics is headquartered

Location

Headquarters

HQ city
Wan Chai
HQ country
Hong Kong SAR China
HQ region
Asia

Offices1 record

Markets served

Codex Genetics business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others

Revenue model

  1. Clinical Genetic Testing Services: Codex Genetics generates revenue through clinical genomic tests ordered by healthcare providers and directly by patients via their E-Shop (shop.codexgenetics.com). Tests include hereditary cancer panels, neurodegenerative disease panels, pharmacogenomics, cardiovascular disorder panels, and cancer screening/monitoring. Costs range from $100 to over $2,000 depending on the test complexity.

Pricing tiers

ModelBillingPrice
Unit PricingOne time/ perpetual licenseHereditary Cancer Panels (e.g., CoGenesis® BRCA-Pro — 29-gene panel)
Unit PricingOne time/ perpetual licenseNeurodegenerative Disease Panels (e.g., CoGenesis® Neuro, Alzheimer's Plasma Biomarker)
Unit PricingOne time/ perpetual licensePharmacogenomics (PGx) Tests
Unit PricingOne time/ perpetual licenseCardiovascular Disorder Panels (e.g., CoGenesis® CVD)

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Codex Genetics product offering

Product offering

Core offering

Codex Genetics operates a clinical molecular diagnostics laboratory providing genetic testing services across hereditary cancer, neurodegenerative disease, pharmacogenomics, cardiovascular disorders, neurodevelopmental conditions, liquid biopsy, and whole-genome sequencing. Tests are delivered under the CoGenesis® brand via Next-Generation Sequencing (Illumina NextSeq 2000) combined with the proprietary CoGenesis® Bioinformatics Platform, and are ordered either by healthcare providers through a dedicated clinical portal or directly by patients via the Codex E-Shop.

Product overview

Codex Genetics offers a molecular diagnostics platform providing genetic testing services across multiple clinical areas including hereditary cancer, neurodegenerative diseases, cardiovascular disorders, neurodevelopmental disorders, drug response (pharmacogenomics), cancer screening, treatment guidance, and monitoring. The portfolio includes branded test panels under the CoGenesis® brand (CoGenesis® Cancer, CoGenesis® Neuro, CoGenesis® BRCA-Pro, CoGenesis® CVD) plus specialized biomarker panels and whole-genome sequencing. The company operates on an NGS-based technology platform using the Illumina NextSeq 2000 System, with bioinformatics analysis powered by the CoGenesis® Bioinformatics Platform. All tests leverage Next-Generation Sequencing for comprehensive analysis and are supported by HKAS HOKLAS accreditation and ISO certifications. The company also provides distribution services for third-party diagnostic products such as the PrecivityAD2 blood test in partnership with C2N Diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

  • CoGenesis Cancer: Hereditary cancer test panels including BRCA-Pro, Gastric, Prostate, and Colo tests using Next-Generation Sequencing
  • CoGenesis Neuro
  • CoGenesis AD
  • CoGenesis CVD
  • CoGenesis Bioinformatics Platform
  • PrecivityAD2

Products and services

  • CoGenesis® Cancer Panel Flagship hereditary cancer test panel using Next-Generation Sequencing to detect risks for hereditary cancers, including BRCA-Pro (29-gene hereditary breast and ovarian cancer), Gastric, Prostate, and Colo panels. Delivered with NCCN-aligned actionable recommendations. Turnaround 4-6 working weeks.
  • CoGenesis® Neuro Panel Comprehensive genomic panel for unexplained neurological disorders, including APOE genotyping for Alzheimer's disease risk assessment. Aimed at neurologists and patients with neurodegenerative concerns. Turnaround 2-4 weeks for AD/APOE components.
  • CoGenesis® BRCA-Pro 29-gene hereditary breast and ovarian cancer test providing risk assessment with well-stratified risk and actionable NCCN-aligned recommendations. Turnaround under 21 days.
  • CoGenesis® CVD Comprehensive hereditary cardiovascular disease panel for identifying genetic predispositions to heart conditions. Turnaround approximately 3-4 working weeks.
  • Alzheimer's Disease Plasma Biomarker Panel Validated plasma biomarkers for Alzheimer's disease combining APOE genotyping via sequencing with single-molecule immuno-detection of p-tau217, Aβ42/40 ratio, and NfL. Turnaround 14-21 working days. Aligned with NIA-AA 2024 criteria.
  • Whole-Genome Sequencing Comprehensive sequencing service covering the entire genome for rare disease diagnoses, diagnostic odyssey resolution, and detailed genetic analysis. Suitable for pediatric developmental delay investigation.
  • Liquid Biopsy Non-invasive blood-based testing for cancer detection, screening, treatment guidance, and monitoring, used in oncology workflows.
  • Pharmacogenomics (PGx) Drug response genetic testing that personalizes medication and treatment plans based on genetic profiles, including gene-drug interaction summaries to prevent adverse drug reactions and inform prescribing.
  • PrecivityAD2 Blood Test Blood-based test for early detection and diagnosis of Alzheimer's disease, distributed by Codex Genetics in Hong Kong under exclusive partnership with C2N Diagnostics; offered to hospitals, specialty clinics, and research centers.

Quantifiable outcome

  • Over 90% accuracy compared to cerebrospinal fluid analysis or amyloid PET analysis for the PrecivityAD2 blood test (JAMA-published clinical care study)
  • +3 more outcomes

Companies that use Codex Genetics

Customer profile

Named customers3 records

Segments7 records

Ideal customer profiles3 records

Codex Genetics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Codex Genetics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • C2N DiagnosticscoreChannel Partner/ Reseller/ Distributor · 10 March 2026Codex Genetics partnered with C2N Diagnostics to launch the PrecivityAD2™ blood test for Alzheimer's disease diagnosis in Hong Kong. C2N provides its proprietary assay technology and analytical platform; Codex Genetics handles local regulatory compliance, distribution, and patient access to hospitals, specialty clinics, and research centers. The collaboration aims to support early intervention strategies and clinical trial enrollment.
  • C2N DiagnosticscoreChannel Partner/ Reseller/ Distributor · 8 August 2025C2N Diagnostics expansion of the PrecivityAD2 blood test to over seven additional countries through six new international partners including Codex Genetics. Codex serves as the exclusive distributor for Hong Kong. The blood test has demonstrated over 90% accuracy compared to cerebrospinal fluid analysis or amyloid PET analysis (JAMA-published study).
  • ZA InsureminorChannel Partner/ Reseller/ DistributorCodex Genetics partners with ZA Insure to enhance test accessibility through insurance coverage, allowing patients to potentially offset testing costs through health insurance.

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Codex Genetics competitors and assessment

Company assessment

Direct peers

  • Prenetics: Hong Kong-headquartered genetic and diagnostic testing company offering hereditary cancer screening, pharmacogenomics, and consumer health tests across Asia. Closest geographic and product peer to Codex Genetics, competing for similar Hong Kong clinical and consumer customers.
  • Macrogen: Asia-based (Korea) genomic services and NGS sequencing provider offering clinical and research sequencing, hereditary cancer panels, and bioinformatics. Comparable to Codex in NGS-based clinical panel offerings and target customers across research and clinical markets.
  • Color Genomics: US-based genetic testing company specializing in hereditary cancer panels and population health genomics. Directly comparable hereditary cancer testing offering and clinical accuracy emphasis to Codex's CoGenesis® Cancer and BRCA-Pro panels.
  • Novogene: China-based genomics services company providing NGS, whole-genome sequencing, and clinical genetic testing across Asia and globally. Directly comparable NGS-based clinical testing menu (hereditary cancer, rare disease, oncology) to Codex's CoGenesis® panels.

Broad incumbents

  • Foundation Medicine: US-based molecular diagnostics company (Roche subsidiary) specializing in comprehensive genomic profiling for cancer. Comparable NGS-based cancer genomics testing capability to Codex's CoGenesis® Cancer and liquid biopsy panels.
  • Natera: US-based genetic testing company with hereditary cancer (Signatera), reproductive health, and organ transplant testing. Comparable NGS-based clinical genetic testing portfolio and oncology-monitoring positioning similar to Codex's liquid biopsy offering.
  • Myriad Genetics: US-based molecular diagnostics leader with strong hereditary cancer franchise (BRACAnalysis, myRisk). Comparable hereditary cancer panel product and NCCN-aligned reporting standard referenced in Codex's BRCA-Pro offering.
  • 23andMe: US-based direct-to-consumer genetic testing company offering health risk and carrier screening tests. Comparable consumer-facing hereditary health risk testing business model, though operating at much larger scale and in different geographies.
  • BGI Group: Largest Chinese genomics conglomerate offering clinical NGS testing, NIFTY prenatal screening, and cancer diagnostics across Asia. Comparable in menu breadth and Asian market focus, with substantially greater scale and vertically integrated sequencing capacity.

Regional players

  • Kingmed Diagnostics: China-based clinical diagnostic laboratory network offering genetic and molecular testing, including hereditary cancer panels, across mainland China. Comparable clinical lab business model with NGS-based testing menu, primarily serving mainland China and not directly competing in Hong Kong.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Codex Genetics social profiles

Digital presence

Codex Genetics compliance and trust

Trust signal

Compliance3 records

Codex Genetics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Codex Genetics leadership team

Management profile

Number of profiles

Profiles2 records

Codex Genetics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Codex Genetics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Codex Genetics

What does Codex Genetics do?

Codex Genetics operates a clinical molecular diagnostics laboratory providing genetic testing services across hereditary cancer, neurodegenerative disease, pharmacogenomics, cardiovascular disorders, neurodevelopmental conditions, liquid biopsy, and whole-genome sequencing. Tests are delivered under the CoGenesis® brand via Next-Generation Sequencing (Illumina NextSeq 2000) combined with the proprietary CoGenesis® Bioinformatics Platform, and are ordered either by healthcare providers through a dedicated clinical portal or directly by patients via the Codex E-Shop.

Is Codex Genetics a public or private company?

Codex Genetics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Codex Genetics founded?

Codex Genetics was founded in 2013. It employs 11 to 50 people.

Where is Codex Genetics based?

Codex Genetics is headquartered in Wan Chai, Hong Kong SAR China, in the Asia region.

How does Codex Genetics make money?

One revenue line is on record: clinical Genetic Testing Services.

Who are Codex Genetics's main competitors?

Direct peers on record are Prenetics, Macrogen, Color Genomics and Novogene. Broad incumbents are Foundation Medicine, Natera, Myriad Genetics, 23andMe and BGI Group. Kingmed Diagnostics is listed as a regional player.

Does Codex Genetics have an API?

No public API is recorded for Codex Genetics.

What industry is Codex Genetics in?

Codex Genetics's product category is Molecular Diagnostics & Genetic Testing Services. Its primary akta.pro industry code is HLAFAMAE, Molecular Diagnostics & Genomics Laboratories, with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals